IL313003A - Tigit- and light-based chimeric proteins - Google Patents

Tigit- and light-based chimeric proteins

Info

Publication number
IL313003A
IL313003A IL313003A IL31300324A IL313003A IL 313003 A IL313003 A IL 313003A IL 313003 A IL313003 A IL 313003A IL 31300324 A IL31300324 A IL 31300324A IL 313003 A IL313003 A IL 313003A
Authority
IL
Israel
Prior art keywords
domain
tigit
light
transmembrane protein
chimeric proteins
Prior art date
Application number
IL313003A
Other languages
English (en)
Hebrew (he)
Original Assignee
Shattuck Labs Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shattuck Labs Inc filed Critical Shattuck Labs Inc
Publication of IL313003A publication Critical patent/IL313003A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/82—Colon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
IL313003A 2017-02-27 2018-02-27 Tigit- and light-based chimeric proteins IL313003A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762464002P 2017-02-27 2017-02-27
PCT/US2018/020037 WO2018157162A1 (en) 2017-02-27 2018-02-27 Tigit- and light-based chimeric proteins

Publications (1)

Publication Number Publication Date
IL313003A true IL313003A (en) 2024-07-01

Family

ID=63253416

Family Applications (2)

Application Number Title Priority Date Filing Date
IL313003A IL313003A (en) 2017-02-27 2018-02-27 Tigit- and light-based chimeric proteins
IL268198A IL268198B2 (en) 2017-02-27 2018-02-27 Tigit- and light-based chimeric proteins

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL268198A IL268198B2 (en) 2017-02-27 2018-02-27 Tigit- and light-based chimeric proteins

Country Status (15)

Country Link
US (8) US11332509B2 (OSRAM)
EP (2) EP3585425A4 (OSRAM)
JP (5) JP7128195B2 (OSRAM)
KR (1) KR102745835B1 (OSRAM)
CN (3) CN118994414A (OSRAM)
AU (2) AU2018223821B2 (OSRAM)
BR (1) BR112019017298A2 (OSRAM)
CA (2) CA3054127A1 (OSRAM)
IL (2) IL313003A (OSRAM)
MX (1) MX2019009812A (OSRAM)
MY (1) MY207687A (OSRAM)
PH (1) PH12019501533A1 (OSRAM)
SG (1) SG11201906465YA (OSRAM)
WO (2) WO2018157162A1 (OSRAM)
ZA (1) ZA201905488B (OSRAM)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7128195B2 (ja) 2017-02-27 2022-08-30 シャタック ラボ，インコーポレイテッド 細胞外ドメインベースのキメラタンパク質の製造方法及び使用方法
EP3687565A1 (en) 2017-09-27 2020-08-05 Alexion Pharmaceuticals, Inc. Methods of improving cardiovascular function and treating cardiovascular disease using a recombinant ectonucleotide pyrophosphatase phosphodiesterase (npp1)
EP3810172A4 (en) * 2018-06-21 2022-04-20 Shattuck Labs, Inc. Heterodimeric proteins and uses thereof
US20210324041A1 (en) * 2018-08-29 2021-10-21 Shattuck Labs, Inc. Combination therapies
WO2020047322A1 (en) * 2018-08-29 2020-03-05 Shattuck Labs, Inc. Combination therapies comprising tim-3-based chimeric proteins
CN112771067A (zh) 2018-08-29 2021-05-07 沙塔克实验室有限公司 包含基于SIRPα的嵌合蛋白的组合疗法
CN120383683A (zh) * 2018-08-31 2025-07-29 耶鲁大学 Enpp1多肽及其使用方法
WO2020051248A1 (en) * 2018-09-05 2020-03-12 Arizona Board Of Regents On Behalf Of Arizona State University Oncolytic virus platform to treat hematological cancer
MX2021005980A (es) 2018-11-21 2021-08-11 Mayo Found Medical Education & Res Adenovirus y metodos para usar adenovirus.
CA3131259A1 (en) * 2019-02-28 2020-09-03 Shattuck Labs, Inc. Combination therapies
CN113710694A (zh) * 2019-04-29 2021-11-26 梅奥医学教育及研究基金会 用于治疗癌症的多价pd-l1结合化合物
CN112111437B (zh) * 2020-05-25 2023-09-05 江南大学 2’-岩藻糖基乳糖产量提高的重组枯草芽孢杆菌及其构建方法
CR20220611A (es) * 2020-06-02 2023-06-07 Arcus Biosciences Inc Anticuerpos anti-tigit
US20210395366A1 (en) 2020-06-18 2021-12-23 Genentech, Inc. Treatment with anti-tigit antibodies and pd-1 axis binding antagonists
TW202216778A (zh) 2020-07-15 2022-05-01 美商安進公司 Ｔｉｇｉｔ及ｃｄ１１２ｒ阻斷
CN111808800B (zh) * 2020-07-20 2022-08-26 中南大学湘雅二医院 一种体外诱导免疫抑制性髓系抑制细胞及其制备和应用
JP2023541996A (ja) * 2020-09-17 2023-10-04 シャタック ラボ，インコーポレイテッド ＳＩＲＰ１αキメラタンパク質の臨床投与
EP4237000A4 (en) * 2020-11-02 2024-09-18 Athae Bio, Inc. TWO-DOMAIN MULTIMERIC FUSION PROTEINS
KR20230129229A (ko) * 2020-12-03 2023-09-07 샤턱 랩스 인코포레이티드 Tigit- 및 light-기반 키메라 단백질을 이용한 암 치료방법
CN116897202A (zh) * 2021-02-24 2023-10-17 科济生物医药（上海）有限公司 Tigit工程化细胞及其组合物
CN115260312B (zh) * 2021-04-30 2025-02-14 保诺科技（北京）有限公司 结合ox40的抗体或抗原结合片段
WO2023010094A2 (en) 2021-07-28 2023-02-02 Genentech, Inc. Methods and compositions for treating cancer
TW202321308A (zh) 2021-09-30 2023-06-01 美商建南德克公司 使用抗ｔｉｇｉｔ抗體、抗ｃｄ３８抗體及ｐｄ—１軸結合拮抗劑治療血液癌症的方法
CN115960247A (zh) * 2021-10-13 2023-04-14 苏州科锐迈德生物医药科技有限公司 基于t7rna聚合酶的融合多肽及其制备方法、用途
EP4426725A2 (en) * 2021-11-01 2024-09-11 Shattuck Labs, Inc. Chimeric proteins for treating cutaneous inflammation
CN114209815B (zh) * 2021-11-22 2024-04-26 山东大学 一种药物组合物及其制备方法和应用
WO2023105281A1 (en) * 2021-12-11 2023-06-15 Fundaciò Privada Institut De Recerca De La Sida-Caixa Soluble tigit recombinant proteins
CN115490771A (zh) * 2021-12-24 2022-12-20 合肥天港免疫药物有限公司 重组抗体及其应用
CN114196691B (zh) * 2021-12-28 2023-08-11 重庆澳龙生物制品有限公司 一种制备防治牛、羊棘球蚴病多表位重组疫苗的基因、蛋白质、疫苗和应用
KR20250022049A (ko) 2022-06-07 2025-02-14 제넨테크, 인크. 항-pd-l1 길항제 및 항-tigit 길항제 항체를 포함하는, 폐암 치료의 효율을 결정하는 방법
CN117624375A (zh) * 2022-08-30 2024-03-01 北京卡替医疗技术有限公司 增强受体、表达增强受体的免疫细胞及其用途
CN116350748A (zh) * 2022-11-01 2023-06-30 中国医学科学院皮肤病医院(中国医学科学院皮肤病研究所) Tigit融合蛋白在制备用于治疗系统性红斑狼疮药物中的应用
WO2024123812A1 (en) 2022-12-05 2024-06-13 Shattuck Labs, Inc. Fusion proteins for the treatment of cardiometabolic diseases
CN116041542A (zh) * 2022-12-06 2023-05-02 上海恩凯细胞技术有限公司 逆转肿瘤微环境抑制性信号的nk细胞制备方法及应用
CN116037072B (zh) * 2023-02-24 2025-01-03 宁夏医科大学 一种血清抗体亲和分离材料的制备方法与应用
CN116925236B (zh) * 2023-05-12 2024-06-04 上海恩凯细胞技术有限公司 嵌合转换受体及其应用
WO2024260419A1 (en) * 2023-06-22 2024-12-26 Fbd Biologics Limited Multi-targeting protein complex and methods of use thereof
CN116982600B (zh) * 2023-09-14 2025-11-18 江苏集萃药康生物科技股份有限公司 一种cd69人源化小鼠模型的构建方法及其应用
CN119930791A (zh) * 2023-11-02 2025-05-06 重庆精准生物技术有限公司 特异性tigit肽段
WO2025140345A1 (zh) * 2023-12-29 2025-07-03 沈阳三生制药有限责任公司 一种tigit多肽及tigit/ctla4融合蛋白

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5844095A (en) 1991-06-27 1998-12-01 Bristol-Myers Squibb Company CTLA4 Ig fusion proteins
WO1993008207A1 (en) 1991-10-25 1993-04-29 Immunex Corporation Novel cytokine
US20110041190A1 (en) 2002-10-31 2011-02-17 Tykocinski Mark L Novel chimeric proteins
AU2926401A (en) 2000-01-03 2001-07-16 Tr Associates, L.L.C. Novel chimeric proteins and methods for using the same
US7696168B2 (en) 2000-04-21 2010-04-13 Tufts Medical Center, Inc. G protein coupled receptor agonists and antagonists and methods of activating and inhibiting G protein coupled receptors using the same
WO2003042402A2 (en) 2001-11-13 2003-05-22 Dana-Farber Cancer Institute, Inc. Agents that modulate immune cell activation and methods of use thereof
WO2005033144A2 (en) 2003-10-03 2005-04-14 Brigham And Women's Hospital Tim-3 polypeptides
DK1682583T3 (da) 2003-11-13 2012-05-07 Hanmi Holdings Co Ltd Proteinkompleksdannelse under anvendelse af immunoglobulinfragment samt fremgangsmåde til fremstilling deraf
JP2006345852A (ja) 2005-06-16 2006-12-28 Virxsys Corp 抗体複合体
CA2652570A1 (en) 2006-05-15 2007-11-22 Viral Logic Systems Technology Corp. Cd47 related compositions and methods for treating immunological diseases and disorders
AU2007257692B2 (en) 2006-06-12 2013-11-14 Aptevo Research And Development Llc Single-chain multivalent binding proteins with effector function
US20110028688A1 (en) 2006-06-21 2011-02-03 Genentech, Inc. Crystal structure of ox40l and ox40l complexed with ox40 receptor
WO2008061377A1 (en) 2006-11-22 2008-05-29 Centre Hospitalier De L'universite De Montreal Novel receptor for cd40l and uses thereof
EP2650018A3 (en) 2007-05-14 2014-09-03 The University of Chicago Antibody-LIGHT fusion products for cancer therapeutics
DK3056515T4 (da) 2008-01-15 2025-10-20 Univ Leland Stanford Junior Fremgangsmåde til at manipulere fagocytose medieret af cd47
EP2262531A1 (en) 2008-03-08 2010-12-22 Immungene, Inc. Engineered fusion molecules immunotherapy in cancer and inflammatory diseases
EP2111869A1 (en) 2008-04-23 2009-10-28 Stichting Sanquin Bloedvoorziening Compositions and methods to enhance the immune system
WO2010005519A1 (en) 2008-06-30 2010-01-14 University Of Pennsylvania Fn14/trail fusion proteins
NZ590667A (en) 2008-07-02 2013-01-25 Emergent Product Dev Seattle Tgf-b antagonist multi-target binding proteins
EP3103875A1 (en) 2008-07-21 2016-12-14 Apogenix AG Tnfsf single chain molecules
WO2010062401A2 (en) 2008-11-26 2010-06-03 Five Prime Therapeutics, Inc. Treatment of osteolytic disorders and cancer using csf1r extracellular domain fusion molecules
WO2010062399A2 (en) 2008-11-26 2010-06-03 Five Prime Therapeutics, Inc. Csf1r extracellular domain fusion molecules and treatments using same
CA2747678A1 (en) * 2008-12-19 2010-06-24 Novartis Ag Soluble polypeptides for use in treating autoimmune and inflammatory disorders
CN103641918A (zh) 2009-03-13 2014-03-19 宾夕法尼亚大学董事会 Ox40/trail融合蛋白
IL323000A (en) * 2010-03-05 2025-10-01 Univ Johns Hopkins Compositions and methods for antibodies and fusion proteins targeted for immune modulation
CN103153332A (zh) 2010-09-28 2013-06-12 卡尔医疗有限公司 用于治疗血液恶性肿瘤的组合物和方法
WO2012062218A1 (en) 2010-11-11 2012-05-18 The University Of Hong Kong Soluble pd-1 variants, fusion constructs, and uses thereof
SI2697257T1 (sl) 2011-04-13 2017-02-28 Bristol-Myers Squibb Company FC fuzijski proteini, ki vsebujejo nove linkerje ali razmestitve
WO2012162565A2 (en) 2011-05-25 2012-11-29 Cel-Sci Corporation Method for inducing an immune response for treatment of cancer and autoimmune diseases or conditions
CN102850458B (zh) * 2011-06-28 2014-10-01 华博生物医药技术（上海）有限公司 新型重组双功能融合蛋白及其制法和用途
EA201490364A1 (ru) 2011-07-29 2014-08-29 Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания Костимулирующие рецепторы-переключатели
ES2740358T3 (es) 2012-02-06 2020-02-05 Providence Health & Services Oregon Método de supervisión del tratamiento del cáncer con agonistas de OX40
ES2938182T3 (es) 2012-04-30 2023-04-05 Biocon Ltd Proteínas de fusión dirigidas/inmunomoduladoras y métodos de preparación de las mismas
ES2924722T3 (es) 2012-05-18 2022-10-10 Aptevo Res & Development Llc Unión de inmunofusión de scFv biespecífico (BIf) a CD123 y CD3
CN112587658A (zh) 2012-07-18 2021-04-02 博笛生物科技有限公司 癌症的靶向免疫治疗
DK2931752T3 (da) 2012-12-17 2019-11-18 Trillium Therapeutics Inc Behandling af cd47+ sygdomsceller med sirp-alpha-fc-fusioner
EP2941438A1 (en) * 2013-01-01 2015-11-11 Kahr Medical Ltd. Stable form of signal converting protein fusion proteins, and methods of use and preparation thereof
US20140242077A1 (en) 2013-01-23 2014-08-28 Abbvie, Inc. Methods and compositions for modulating an immune response
WO2014121085A1 (en) 2013-01-31 2014-08-07 Thomas Jefferson University Pd-l1 and pd-l2-based fusion proteins and uses thereof
WO2015116178A1 (en) 2014-01-31 2015-08-06 Thomas Jefferson University Fusion proteins for modulating regulatory and effector t cells
US10533054B2 (en) 2013-01-31 2020-01-14 Thomas Jefferson University Agonist fusion protein for CD40 and OX40 and methods of stimulating the immune system
WO2014121093A1 (en) 2013-01-31 2014-08-07 Thomas Jefferson University Fusion proteins that facilitate cancer cell destruction
EP2951199A4 (en) 2013-01-31 2016-07-20 Univ Jefferson Fusion proteins for the modulation of regulatory and effector T cells
KR102363191B1 (ko) 2013-02-26 2022-02-17 메모리얼 슬로안 케터링 캔서 센터 면역치료용 조성물 및 방법
EP2970512B1 (en) 2013-03-12 2018-10-10 Biocon Limited Fusion immunomodulatory proteins and methods for making same
SG11201601844TA (en) 2013-09-13 2016-04-28 Beigene Ltd Anti-pd1 antibodies and their use as therapeutics and diagnostics
US10144770B2 (en) * 2013-10-17 2018-12-04 National University Of Singapore Chimeric receptors and uses thereof in immune therapy
US10196435B2 (en) 2013-11-18 2019-02-05 University Of Southern California OX40L fusion protein for the immunotherapy of tumors of veterinary animals
BR112016013963A2 (pt) 2013-12-17 2017-10-10 Genentech Inc terapia de combinação compreendendo agonistas de ligação de ox40 e antagonistas de ligação do eixo de pd-1
WO2015104406A2 (en) 2014-01-13 2015-07-16 Pieris Ag Multi-specific polypeptide useful for localized tumor immunomodulation
CN106170498A (zh) 2014-01-14 2016-11-30 科马布有限公司 抗‑light抗体
CA2936244A1 (en) 2014-01-21 2015-07-30 Medimmune, Llc Compositions and methods for modulating and redirecting immune responses
WO2015148416A1 (en) 2014-03-24 2015-10-01 Deqiang Jing Novel recombinant bi-functional fusion proteins, preparation and use thereof
CN106456734A (zh) 2014-05-29 2017-02-22 免疫医疗有限责任公司 Ox40l融合蛋白及其用途
EP3160497A4 (en) 2014-06-27 2018-01-17 H. Lee Moffitt Cancer Center And Research Institute, Inc. Conjugates for immunotherapy
CN113621075B (zh) 2014-08-08 2024-09-20 Alx肿瘤生物技术公司 SIRP-α变体构建体及其用途
PL3482766T3 (pl) 2014-08-11 2020-11-16 Delinia, Inc. Modyfikowane warianty il-2, które selektywnie aktywują limfocyty t regulatorowe do leczenia chorób autoimmunologicznych
LT3180363T (lt) 2014-08-15 2019-11-25 Merck Patent Gmbh Sirp-alfa imunoglobulino sulieti baltymai
KR20170096112A (ko) 2014-11-17 2017-08-23 제넨테크, 인크. Ox40 결합 효능제 및 pd-1 축 결합 길항제를 포함하는 조합 요법
WO2016090347A1 (en) 2014-12-05 2016-06-09 Immunext, Inc. Identification of vsig8 as the putative vista receptor and its use thereof to produce vista/vsig8 modulators
WO2016112983A1 (en) * 2015-01-15 2016-07-21 Biontech Ag Cytokine fusion proteins
US11161907B2 (en) * 2015-02-02 2021-11-02 Novartis Ag Car-expressing cells against multiple tumor antigens and uses thereof
MA41460A (fr) 2015-02-03 2017-12-12 Oncomed Pharm Inc Agents de liaison à la tnfrsf et leurs utilisations
BR112017016681A2 (pt) 2015-02-06 2018-04-10 Heat Biologics Inc vetor de coexpressão de vacina e moléculas coestimulatórias
WO2016166139A1 (en) * 2015-04-14 2016-10-20 Eberhard Karls Universität Tübingen Bispecific fusion proteins for enhancing immune responses of lymphocytes against tumor cells
DK3298043T3 (da) 2015-05-18 2021-02-15 Ab Initio Biotherapeutics Inc SIRP-polypeptidsammensætninger og fremgangsmåder til anvendelse
IL294679B2 (en) 2015-08-07 2023-10-01 Alx Oncology Inc Structures with a SIRP-alpha site or its variant
IL316210A (en) 2015-10-01 2024-12-01 Heat Biologics Inc Compounds and methods for connecting type 1 and 2 extracellular complexes as heterologous chimeric proteins
WO2018075960A1 (en) 2016-10-21 2018-04-26 Tioma Therapeutics, Inc. Therapeutic cd47 antibodies
JP7128195B2 (ja) * 2017-02-27 2022-08-30 シャタック ラボ，インコーポレイテッド 細胞外ドメインベースのキメラタンパク質の製造方法及び使用方法

Also Published As

Publication number Publication date
US20220227831A1 (en) 2022-07-21
ZA201905488B (en) 2024-02-28
KR20190122667A (ko) 2019-10-30
SG11201906465YA (en) 2019-08-27
CN110234345A (zh) 2019-09-13
RU2019125682A3 (OSRAM) 2021-12-03
IL268198B2 (en) 2024-10-01
EP3585425A4 (en) 2020-10-28
EP3585418A1 (en) 2020-01-01
US20200283496A1 (en) 2020-09-10
JP2022159510A (ja) 2022-10-17
IL268198B1 (en) 2024-06-01
US20190367579A1 (en) 2019-12-05
KR102745835B1 (ko) 2024-12-24
US20200222503A1 (en) 2020-07-16
EP3585418A4 (en) 2020-11-25
US20240368242A1 (en) 2024-11-07
JP7260477B2 (ja) 2023-04-18
RU2019125682A (ru) 2021-03-29
WO2018157162A1 (en) 2018-08-30
US20220315637A1 (en) 2022-10-06
US10899817B2 (en) 2021-01-26
CN110381983A (zh) 2019-10-25
MY207687A (en) 2025-03-12
CA3054127A1 (en) 2018-08-30
CA3054133A1 (en) 2018-03-30
JP2023076695A (ja) 2023-06-01
US10927159B2 (en) 2021-02-23
AU2018223821A1 (en) 2019-07-11
WO2018157165A1 (en) 2018-08-30
JP7620045B2 (ja) 2025-01-22
AU2018223821B2 (en) 2022-05-19
PH12019501533A1 (en) 2020-02-24
BR112019017298A2 (pt) 2020-04-14
US11332509B2 (en) 2022-05-17
AU2022218575A1 (en) 2022-11-10
US20240190939A1 (en) 2024-06-13
US12071465B2 (en) 2024-08-27
JP2025061180A (ja) 2025-04-10
JP2020508329A (ja) 2020-03-19
JP2020508068A (ja) 2020-03-19
JP7128195B2 (ja) 2022-08-30
EP3585425A1 (en) 2020-01-01
CN110381983B (zh) 2024-07-09
IL268198A (en) 2019-09-26
US20200399342A1 (en) 2020-12-24
CN118994414A (zh) 2024-11-22
MX2019009812A (es) 2019-10-14

Similar Documents

Publication Publication Date Title
IL313003A (en) Tigit- and light-based chimeric proteins
CO6231038A2 (es) Proteinas de union, incluyendo anticuerpos derivados de anticuerpo y fragmentos de anticuerpo que se unen especificamente a cd154 y sus usos
WO2015138907A3 (en) Hybrid immunoglobulin containing non-peptidyl linkage
CY1118343T1 (el) Αντισωματα συνδεσης twεακ
EA202191105A1 (ru) Слитые белки, полученные из глюкагоноподобного пептида 1 (glp1) и ростового фактора дифференцировки 15 (gdf15), и их применение
EP2507267A4 (en) COMPOSITIONS AND METHODS FOR INCREASING THE SERUM DURABILITY OF FC FUSION PROTEINS
HK1249528A1 (zh) 通过c-末端合成半胱氨酸连接的纳米抗体二聚体
PA8807601A1 (es) Moleculas de union al receptor ox40 humano
JP2016538240A5 (OSRAM)
DK2046951T5 (da) Proteasesreeningsmetoder og proteaser identificeret dermed
EP1871785A4 (en) COMPOSITIONS AND METHOD FOR SEPARATING FUSION PROTEINS
NO20092414L (no) Modifiserte loselige FGF-reseptor FC-fusjoner med forbedret biologisk aktivitet
WO2005087810A3 (en) Dimeric fusion proteins and materials and methods for producing them
DK1553975T3 (da) Optimerede Fc-varianter og fremgangsmåder til generering heraf.
EA200700210A1 (ru) ВАРИАНТЫ ОБЛАСТИ Fc
UY38194A (es) Proteína de fusión
WO2007064919A3 (en) Binding polypeptides with restricted diversity sequences
DK1761553T3 (da) MHC molecule-binding tumor-associated peptides
EP4382167A3 (en) Compounds comprising a linker for increasing transcyclooctene stability
SG171670A1 (en) Rage fusion proteins, formulations, and methods of use thereof
PE20090225A1 (es) Proteinas de fusion que degradan el peptido beta amiloide
EA202091054A1 (ru) Слитые молекулы на основе антитела против pd-l1 и ил-7
CY1116269T1 (el) Χρηση μιας πρωτεϊνης απο λουπινο
DK2007885T3 (da) Fremgangsmåde til forøgelse af in vivo-genvindingen af terapeutiske polypeptider
MX381726B (es) Cadena alfa del receptor de inmunoglobulina e (ige) de alta afinidad de fusion de fragmento cristalizable (fc).